Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Current Status and Consensus on Esophageal Cancer Management

식도암의 치료, 어디까지 와 있는가?

  • Joon Han Jeon (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Dae Young Cheung (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • 전준한 (가톨릭대학교 의과대학 내과학교실) ;
  • 정대영 (가톨릭대학교 의과대학 내과학교실)
  • Received : 2012.11.07
  • Accepted : 2012.12.22
  • Published : 2013.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Over the decades, the treatment of the esophageal cancer has been debated. Multimodal therapy is a important keystone in advanced esophageal cancer. Neoadjuvant chemoradiation therapy is now known to provide advantages for treating stage II and stage III esophageal squamous cell cancer and can also be considered for the esophageal adenocarcinoma. Definitive chemoradiation therapy results in long-term survival compared with surgery alone. This review aims to provide recent consensus recommendations based on the data and literatures.

식도암의 치료는 근치적 절제와 화항방사선치료를 포함하는 다중치료가 보편적으로 받아들여지고 있다. 그러나 치료의 종양학적 결과는 충분히 만족스러운 수준에 이르고 있지 못하다. 이에 대하여 기존 항암 화학요법과 방사선치료, 수술 그리고 표적약물의 적용에 대한 연구가 지속되고 있다. 이 논문에서는 문헌과 보고를 근거로 식도암 치료에 대한 최근의 합의과 권고를 정리하였다.

Keywords

References

  1. Natsugoe S, Matsumoto M, Okumura H, et al. Multiple primary carcinomas with esophageal squamous cell cancer: clinicopathologic outcome. World J Surg 2005;29:46-49.
  2. Lagergreen J. Oesophageal cancer and gastro-oesophageal reflux: what is the relationship? Gut 2004;53:1064-1065.
  3. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-1383.
  4. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150.
  5. Pohl H, Sirovich B, Welch G. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010;19:1468-1470.
  6. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. JohnWiley & Sons, Chichester, UK, 2010.
  7. Holscher AH, Bollschweiler E, Schroder W, Metzger R, Gutschow C, Drebber U. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg 2011;254:802-807.
  8. Gertler R, Stein HJ, Langer R, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg 2011;253:689-698.
  9. van Westreenen HL, Westerterp M, Sloof GW, et al. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 2007;94:1515-1520.
  10. Kelly S, Harris KM, Berry E, et al. A systematic review of the staging performance of endoscopic ultrasound on gastrooesophageal carcinoma. Gut 2001;49:534-539.
  11. Rosch T. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am 1995;5:537-547.
  12. Monig SP, Schroder W, Baldus SE, Holscher AH. Preoperative lymph node staging in gastrointestinal cancer-correlation between size and tumour stage. Onkologie 2000;25:342-344.
  13. Pech O, Bollschweiler E, Manner H, et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 2011;254:67-72.
  14. Kranzfelder M, Schuster T, Geinitz H, et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for esophageal squamous cell cancer. Br J Surg 2011;98:768-783.
  15. Steyerberg EW, Neville BA, Koppert LB, et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006;24: 4277-4284.
  16. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma. I. A critical review of surgery. Br J Surg 1980;67:381-390.
  17. Omloo JMT, Lagarde SM, Hulscher JBF, et al. Extended transthoracic resection compared with limited transhiatal resection for adneocarcinoma of the mid/distal esophagus: five year survival of a randomized clinical trial. Ann Surg 2007;246:992-1000.
  18. Orringer MB, Marshall B, Chang AC, et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg 2007;246:363-374.
  19. Goldminc M, Madden G, Leprise E, et al. Oesphagectomy by a transhiatal approach or thoracotomy a randomized trial. Br J Surg 1993;80:367-370.
  20. Gutschow C, Schroder W, Wolfgarten E, Holscher AH. Operation nach Merendino mit Vaguserhaltung beim Fruhkarzinom des gastroosophagealen ubergangs. Zentralbl Chir 2004;129:276-281.
  21. Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008;248:549-556.
  22. Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 2006;132:1374-1381.
  23. Wilson M, Rosato EL, Chojnacki KA, et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res 2008;146:11-15.
  24. Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008;247:365-371.
  25. Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol 2012;23(5):21095-21103.
  26. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-692.
  27. Sun DR. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys 1989;16:329-334.
  28. Okawa T, Kita M, Tanaka M, et al. Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 1989;17:49-54.
  29. Nakayama K, Orihata H, Yamaguchi K. Surgical treatment combined with preoperative concentrated irradiation for esophageal cancer. Cancer 1967;20:778-788.
  30. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev (4):CD001799, 2005.
  31. Kasai M, Mori S, Watanabe T. Follow-up results after resection of thoracic esophageal carcinoma. World J Surg 1978;2:543-551.
  32. Fok M, Sham JS, Choy D, et al. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993;113:138-147.
  33. Teniere P, Hay JM, Fingerhut A, et al. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 1991;173:123-130.
  34. Agha FP, Gennis MA, Orringer MB, et al. Evaluation of response to preoperative chemotherapy in esophageal and gastric cardia cancer using biphasic esophagrams and surgical pathologic correlation. Am J Clin Oncol 1986;9:227-232.
  35. Forastiere AA, Gennis M, Orringer MB, et al. Cisplatin, vinblastine, and mitoguazone chemotherapy for epidermoid and adenocarcinoma of the esophagus. J Clin Oncol 1987;5:1143-1149.
  36. Schlag P, Herrmann R, Raeth V, et al. Preoperative chemotherapy in esophageal cancer. A phase II study. Acta Oncol 1988;27:811-814.
  37. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005;23:4330-4337.
  38. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-2084.
  39. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-930.
  40. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856.
  41. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002;183:274-279.
  42. Malthaner R, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Systematic Reviews, 2003.
  43. Greer SE, Goodney PP, Sutton JE, Birkmeyer JD. Neoadjuvant chemoradiation for esophageal carcinoma: a metaanalysis. Surgery 2005;137:172-179.
  44. Urschel JD, Vasan H. A meta-analysis of randomised controlled trials that compared neoadjuavnt chemoradiation and surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-543.
  45. Abou-Jawde JM, Mekhail T, Adelstein DJ, et al. Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer. Chest 2005;128:250-256.
  46. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002;359:1727-1733.
  47. Kleinberg L, Gibson MK, Forastiere AA. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat Clin Pract Oncol 2007;4:282-294.
  48. Minsky B, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1151-1153.
  49. Lordick F, Ebert M, Stein HJ. Current treatment approach to locally advanced esophageal cancer: Is resection mandatory? Future Oncol 2006;2:717-721.
  50. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317.
  51. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667-1673.
  52. Luber B, Deplazes J, Keller G, et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 2011;11:509
  53. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;229:4803-4810.
  54. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011;8(8):492-503.
  55. Campbell N, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010;16(30):3793-3808.
  56. Gore E, Curry A, Choong N. Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy. Thor Oncol 2009;4:1590-1591.
  57. Spiegel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiaiton and bevacizumab. J Clin Oncol 2010;28:43-48.